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Chloroquine (CQ) has been shown to inhibit HIV-1 rep-
lication in vitro as well as in vivo, thereby indicating its use
as an effective drug in limiting mother to child transmis-
sion of HIV-1 during breastfeeding. We show that HIV-1
replication on CD4+ T-lymphocytes can be reduced in the
presence of CQ and show that the reduced replication is
producer cell specific and that viruses generated in the
presence of CQ are not inhibited for their subsequent
infectivity and replication. By analysing the gp120 enve-
lope protein sequences from virus passaged over a long
period of time in the presence or absence of CQ we dem-
onstrate variant evolution patterns of the envelope. We
also demonstrate that HIV-1 produced in the presence of
CQ have a reduced capacity for the transfer by Raji-DC-
SIGN cells to CD4+ T-lymphocytes indicating another
means whereby virus replication may be reduced in vivo.
We conducted a Phase I/II, randomized, placebo-control-
led study to evaluate chloroquine (CQ) administration to
reduce HIV-1 RNA levels in human milk. Thirty HIV-1
positive pregnant Rwandese women (CQ n = 20; placebo
n = 10) were enrolled in a 16 week study, with the treat-
ment group receiving a 200 mg oral dose of CQ daily.
Base-line plasma viral load (pVL) measurements and CD4
counts were determined prior to delivery with pVL, breast
milk VL (bmVL) and CQ levels measured at wk0, wk8 and
wk16. For selected mothers the envelope C1C4 gp120
region was DNA sequenced and analyzed. A higher con-
centration of CQ in breast milk compared to plasma (over
2.5 fold) was observed after 8 and 16 weeks of treatment.
CQ levels in plasma correlated to those in the left and
right breast milk (P = 0.002 and P = 0.003, respectively).
Additionally, a link between high CQ concentrations in
plasma and high CD4 counts (P < 0.001) was observed.
No alterations in bmVL were observed with CQ treatment
whilst pVL increased significantly (P = 0.001). In over half
of the CQ treated individuals there was a greater than 5
fold increase in pVL which was observed by week 8 of
treatment. No specific alterations in the gp120 envelope
sequences could be associated with CQ treatment. Our
results indicate that CQ administration is associated with
increased pVL in early breastfeeding mothers from
Rwanda which cautions against the use of CQ in such
individuals.
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